Provided by Tiger Trade Technology Pte. Ltd.

CINGULATE INC.

6.39
+0.11001.75%
Post-market: 6.21-0.1800-2.82%19:57 EDT
Volume:370.69K
Turnover:2.29M
Market Cap:74.31M
PE:-1.44
High:6.43
Open:6.21
Low:5.99
Close:6.28
52wk High:11.89
52wk Low:3.20
Shares:11.63M
Float Shares:10.72M
Volume Ratio:0.59
T/O Rate:3.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4408
EPS(LYR):-10.1953
ROE:-450.60%
ROA:-83.25%
PB:29.62
PE(LYR):-0.63

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14, 2025

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

TIPRANKS
·
Nov 13, 2025

Biopharma firm Cingulate's Q3 net loss widens, misses analyst expectations

Reuters
·
Nov 13, 2025

Cingulate Inc. posts third quarter loss of $6.0 million

Reuters
·
Nov 13, 2025

Cingulate Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Bryan Wade Downey

Reuters
·
Nov 11, 2025

Cingulate Inc. Appoints Bryan Downey as Chief Commercial Officer

Reuters
·
Nov 10, 2025

Press Release: Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

Dow Jones
·
Nov 10, 2025

BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301

Reuters
·
Oct 28, 2025

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

GlobeNewswire
·
Oct 28, 2025

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

GlobeNewswire
·
Oct 24, 2025

Cingulate Is Maintained at Buy by Roth Capital

Dow Jones
·
Oct 16, 2025

Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success

TIPRANKS
·
Oct 15, 2025

Cingulate price target raised to $17 from $10 at Roth Capital

TIPRANKS
·
Oct 15, 2025

FDA Accepts Cingulate’s New Drug Application for Ctx-1301 in Attention-Deficit/Hyperactivity Disorder (Adhd) and Sets a May 31, 2026 Pdufa Date

THOMSON REUTERS
·
Oct 14, 2025

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

GlobeNewswire
·
Oct 14, 2025